Loading...
Bilateral Trade Intelligence · $4.0K Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $4.0K worth of pharmaceutical formulations from Lao People'S Democratic R across 2 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are DR. DOUANGCHANN KONGPHALY ($4.0K). The leading products are Plasma ($4K). Average shipment value: $2.0K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Plasma | $4.0K | 100.0% |
India imports 1+ pharmaceutical formulations from Lao People'S Democratic R with a combined trade value of $4.0K. Key products include Plasma ($4K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Lao People'S Democratic R, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Lao People'S Democratic R buyers, regulatory requirements, and logistics for that specific product corridor. Products include Plasma ($4K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Lao People'S Democratic R. Leading exporters include Dr. Douangchann Kongphaly, . The top exporter accounts for 100.0% of total India–Lao People'S Democratic R pharma exports. Source: Indian Customs (DGFT).
1 companies in Lao People'S Democratic R import pharmaceutical formulations from India. Top buyers include . The largest buyer accounts for 100.0% of India–Lao People'S Democratic R pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between the Lao People's Democratic Republic (Lao PDR) and India has remained relatively modest over the past decade. In 2015, Lao PDR's pharmaceutical exports to India were valued at approximately $1.21 million. By 2023, this figure had increased to $82.93 million, indicating a significant growth trajectory. This surge reflects a strengthening bilateral trade relationship, with Lao PDR emerging as a more prominent supplier in the Indian pharmaceutical market.
Between 2024 and 2026, there have been no publicly documented policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically affecting pharmaceutical imports from Lao PDR. Similarly, there are no records of new trade agreements or regulatory harmonization efforts between India and Lao PDR during this period. The trade dynamics have remained stable, with existing regulations and agreements continuing to govern the import of pharmaceutical products from Lao PDR into India.
Registration process, GMP requirements, import documentation
For Lao PDR companies aiming to export pharmaceutical products to India, obtaining registration with the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:
1. Online Registration: Applicants must visit the CDSCO Sugam portal and create an account by providing necessary details such as applicant type, username, password, and contact information.
2. Application Submission: After account activation, applicants should log in to the portal, select the appropriate registration form, and complete it with accurate information about the applicant organization and authorized representatives.
3. Document Upload: Essential documents include:
4. Verification and Approval: Upon submission, the application undergoes verification by CDSCO officials. This may include site inspections to ensure compliance with regulatory standards.
5. Issuance of Registration Certificate: Once approved, the registration certificate is issued, authorizing the company to import pharmaceutical products into India.
The entire process is conducted online, facilitating a streamlined and efficient registration experience.
India requires that manufacturing facilities in Lao PDR adhere to Good Manufacturing Practice (GMP) standards to ensure the quality and safety of pharmaceutical products. GMP certification is granted to facilities that comply with these guidelines, which encompass quality assurance procedures and control measures. Additionally, the World Health Organization (WHO) prequalification is often sought to demonstrate that products meet international standards. CDSCO may conduct inspections of manufacturing sites to verify compliance with these standards before granting approval for importation.
To import pharmaceutical products into India, companies must obtain an import license (Form 10) from CDSCO. This license is essential for the legal importation and distribution of drugs and medical devices. Other required documents include:
Adhering to these documentation requirements ensures a smooth import process and compliance with Indian regulatory standards.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Lao PDR are predominantly in specialized product categories. The available data indicates that plasma is the primary product imported, accounting for the entire import value in the reported period. This suggests a focused trade relationship, with Lao PDR supplying specific pharmaceutical products that meet India's needs in this area.
The data does not provide specific information on innovator drugs, novel formulations, or advanced therapies imported from Lao PDR to India. However, the import of specialized products like plasma indicates that Lao PDR may offer unique pharmaceutical products not widely available in India, catering to specific medical requirements.
India's import of pharmaceutical products from Lao PDR is likely driven by factors such as the availability of specialized products, quality standards, and the need to meet specific medical demands. The import of plasma suggests a demand for high-quality, specialized medical supplies that may not be sufficiently produced domestically.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These tariffs and taxes are subject to change based on government policies and international trade agreements.
As of the latest available data, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Lao PDR concerning pharmaceutical imports. Both countries are members of the Regional Comprehensive Economic Partnership (RCEP), which aims to enhance trade relations among member nations. However, the impact of RCEP on pharmaceutical trade between India and Lao PDR has not been explicitly documented.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by restricting the patentability of new forms of known substances unless they result in enhanced efficacy. This provision can impact the import of certain pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. Compulsory licensing provisions allow the government to grant licenses to produce patented products without the consent of the patent holder under specific conditions, such as public health emergencies.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical products from Lao PDR to India are typically transported via sea and air routes. Major sea routes involve shipping from Lao PDR's nearest ports to Indian ports, with transit times varying based on the specific ports and shipping lines used. Air freight offers faster delivery but at a higher cost. The reliability of these routes is generally high, with established shipping lines and air cargo services facilitating regular shipments.
Lao PDR's export ports, such as the Port of Vientiane, handle pharmaceutical shipments. In India, ports like the Jawaharlal Nehru Port Trust (JNPT) in Mumbai and the Chennai Port are equipped to handle pharmaceutical imports, ensuring compliance with international shipping standards and regulations.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation, inspection of goods, and payment of applicable duties and taxes. The Central Drugs Standard Control Organisation (CDSCO) conducts testing to ensure compliance with Indian quality standards. Cold chain management is critical for temperature-sensitive products; facilities at ports and during transit are equipped to maintain required temperatures. Good Distribution Practice (GDP) compliance ensures that products are stored and transported under conditions that maintain their quality and efficacy.
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports specialized products from Lao PDR, such as plasma, to meet specific medical needs. This dependency arises due to factors like the availability of
India exported pharmaceuticals worth $4.0K to Lao People'S Democratic R across 2 verified shipments.
1. DR. DOUANGCHANN KONGPHALY — $4.0K. Total: 1 suppliers.
1. YASHRAJ BIOTECHNOLOGY LIMITED — $4.0K. 1 buyers total.
1. Plasma ($4.0K, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $4.0K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$2.0K per consignment across 2 shipments.
1 Indian companies. Largest: DR. DOUANGCHANN KONGPHALY with $4.0K.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists